Gadolinium-promoted precipitation of calcium phosphate is associated with profibrotic activation of RAW 264.7 macrophages

Toxicology in Vitro

Volumn 24, Issue 6, 2010, Pages 1743-1749

  Gou, Bao Di ^a   Bian, Sha ^a   Zhang, Tian Lan ^a   Wang, Kui ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Calcium phosphate; Cytokine; Gadolinium; Macrophage; Nephrogenic systemic fibrosis

Indexed keywords

CALCIUM PHOSPHATE; GADOLINIUM CHLORIDE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CELL STRAIN; CELL STRAIN RAW 264.7; CHEMICAL COMPOSITION; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; MACROPHAGE ACTIVATION; MOUSE; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PARTICLE SIZE; PATHOGENESIS; PRECIPITATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; CALCIUM PHOSPHATES; CELL LINE; CELL SURVIVAL; CHEMICAL PRECIPITATION; FIBROSIS; GADOLINIUM; INTERLEUKIN-6; MACROPHAGES; MICE; PARTICLE SIZE; SPECTROMETRY, X-RAY EMISSION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77956172315     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2010.05.004     Document Type: Article

References (44)

1. Altun E., Martin D.R., Wertman R., Lugo-Somolinos A., Fuller E.R., Semelka R.C. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy - report from two U.S. universities. Radiology 2009, 253:689-696.
2. Aneea T.K., Palanichamy M., Ashoka M., Sundarama N.M., Kalkuraa S.N. Influence of iron and temperature on the crystallization of calcium phosphates at the physiological pH. Mater. Lett. 2004, 58:478-482.
3. 3 and Gd-DTPA and their influence on proton magnetic relaxation in rat tissues. Magn. Reson. Imaging 1987, 5(3):221-231.
4. Bigi A., Foresti E., Gandolfi M., Gazzano M., Roveri N. Inhibiting effect of zinc on hydroxylapatite crystallization. J. Inorg. Biochem. 1995, 58:49-58.
5. Boyd A.S., Zic J.A., Abraham Jerrold L. Gadolinium deposition in nephrogenic fibrosing dermopathy. J. Am. Acad. Dermatol. 2007, 56:27-30.
6. Dobrota D.B.M. Distribution and excretion of lanthanides: comparison between europium salts and complexes. Biometals 1994, 7:142-148.
7. Edward M., Quinn J., Mukherjee S., Jensen M.-B., Jardine A., Mark P., Burden A. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J. Pathol. 2008, 214:584-593.
8. Gabbiani G., Jacqmin M.L., Richard R.M. Soft-tissue calcification induced by rare earth metals and its prevention by sodium pyrophosphate. Br. J. Phannac. Chenother. 1966, 27:1-9.
9. Garrett I.R., McClure J. Lanthanide-induced calcergy. J. Pathol. 1981, 135(4):267-275.
10. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol. Dial. Transplant. 2006, 21:1104-1108.
11. Hasegawa M., Fujimoto M., Takehara K., Sato S. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis. J. Dermatol. Sci. 2005, 39:1-7.
12. High W.A., Ayers R.A., Chandler J., Zito G., Cowper S.E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J. Am. Acad. Dermatol. 2007, 56:21-26.
13. Hirano S., Suzuki K.T. Exposure, metabolism, and toxicity of rare earths and related compounds. Environ. Health Perspect. 1996, 104(Suppl. 11):85-95.
14. Idée J.-M., Port M., Robic C., Medina C., Sabatou M., Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J. Magn. Reson. Imaging 2009, 30:1249-1258.
15. Jiménez S.A., Artlett C.M., Sandorfi N., Derk C., Latinis K., Sawaya H., Haddad R., Shanahan J.C. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor β1 expression in affected skin. Arthritis Rheum. 2004, 50(8):2660-2664.
16. Jonge L.T.d., Beucken J.J.J.P.v.d., Leeuwenburgh S.C.G., Hamers A.A.J., Wolke J.G.C., Jansen J.A. In vitro responses to electrosprayed alkaline phosphatase/calcium phosphate composite coatings. Acta Biomater. 2009, 5:2773-2782.
17. Kanal E., Broome D.R., Martin D.R., Thomsen H.S. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. Radiology 2008, 246:11-14.
18. Koutsoukos P.G., Kofina A.N., Kanellopoulou D.G. Solubility of salts in water: key issue for crystal growth and dissolution processes. Pure Appl. Chem. 2007, 79(5):825-850.
19. Kubota Y., Takahashi S., Takahashi I., Patrick G. Different cytotoxic response to gadolinium between mouse and rat alveolar macrophages. Toxicol. in Vitro 2000, 14:309-319.
20. Kuo P.H. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications. Am. J. Roentgenol. 2008, 191:1861-1863.
21. Kurtkoti J., Snow T., Hiremagalur B. Gadolinium and nephrogenic systemic fibrosis: association or causation. Nephrology 2008, 13:235-241.
22. Lazar G. The reticuloendothelial-blocking effect of rare earth metals in rats. J. Reticuloendothel. Soc. 1973, 13(3):231-237.
23. 2O) and its transformation to octacalcium phosphate and apatite. J. Cryst. Growth 2008, 310:2602-2612.
24. 2O) transformation in DMEM solutions at 36.5°C. Mater. Sci. Eng. C 2010, 30:245-254.
25. Marckmann P., Skov L., Rossen K., Dupont A., Damholt M.B., Heaf J.G., Thomsen H.S. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J. Am. Soc. Nephrol. 2006, 17:2359-2362.
26. Mizgerd J., Molina R., Stearns R., Brain J., Warner A. Gadolinium induces macrophage apoptosis. J. Leuk. Biol. 1996, 59(2):189-195.
27. Nadra I., Mason J.C., Philippidis P., Florey O., Smythe C.D.W., McCarthy G.M., Landis R.C., Haskard D.O. Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase c and map kinase pathways. Circ. Res. 2005, 96:1248-1256.
28. Newton B.B., Jimenez S.A. Mechanism of NSF: new evidence challenging the prevailing theory. J. Magn. Reson. Imaging 2009, 30:1277-1283.
29. Perazella M.A. Tissue deposition of gadolinium and development of NSF: a convergence of factors. Semin. Dial. 2008, 21(2):150-154.
30. Prchal D., Holmes D., Levin A. Nephrogenic systemic fibrosis: the story unfolds. Kid. Int. 2008, 73:1135-1137.
31. Prince M.R., Zhang H.L., Roditi G.H., Leiner T., Kucharczyk W. Risk factors for NSF: a literature review. J. Magn. Reson. Imaging 2009, 30:1298-1308.
32. Provenzale J.M. Nephrogenic systemic fibrosis: some considerations on the debate regarding its cause. Am. J. Roentgenol. 2008, 191:1867-1869.
33. Rofsky N.M., Sherry A.D., Lenkinski R.E. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 2008, 247:608-612.
34. Rota, E., Nallino, M.G., Bainotti, S., Formica, M., 2009. Nephrogenic systemic fibrosis: an unusual scleroderma-like fibrosing disorder. Rheumatol. Int., doi:10.1007/s00296-009-1083-4.
35. Salimi M.H., Heughebaert J.C., Nancollas G.H. Crystal growth of calcium phosphates in the presence of magnesium ions. Langmuir 1985, 1(1):119-122.
36. Schroeder J.A., Weingart C., Coras B., Hausser I., Reinhold S., Mack M., Seybold V., Vogt T., Banas B., Hofstaedter F., Krämer B.K. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin. J. Am. Soc. Nephrol. 2008, 3:968-975.
37. Shabana W.M., Cohan R.H., Ellis J.H., Hussain H.K., Francis I.R., Su L.D., Mukherji S.K., Swartz R.D. Nephrogenic systemic fibrosis: a report of 29 cases. Am. J. Roentgenol. 2008, 190:736-741.
38. Sherry A.D., Caravan P., Lenkinski R.E. Primer on gadolinium chemistry. J. Magn. Reson. Imaging 2009, 30:1240-1248.
39. Song J., Volkov S., Shea C.R., Alegre M.-L., Salgia R., Gregg K., Curran J.J., Woodruff J., Krausz T., Levine J.S., Sweiss N.J. Nephrogenic systemic fibrosis associated with stromal and vascular calcification, report of two cases. J. Cutan. Pathol. 2009, 36(Suppl. 1):31-34.
40. Spencer A.J., Wilson S.A., Batchelor J., Reid A., Pees J., Harpur E. Gadolinium chloride toxicity in the rat. Toxicol. Pathol. 1997, 25:245-255.
41. Steger-Hartmann T., Raschke M., Riefke B., Pietsch H., Sieberb J.W. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp. Toxicol. Pathol. 2009, 61:537-552.
42. Swaminathan S., High W.A., Ranville J., Horn T.D., Hiatt K., Thomas M., Brown H.H., Shah S.V. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int. 2008, 73:1413-1418.
43. Wermuth P.J., Galdo F.D., Jiménez S.A. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum. 2009, 60(5):1508-1518.
44. Wynn T. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214:199-210.